Renaissance Group LLC acquired a new stake in shares of Sanofi (NYSE:SNY) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 326,142 shares of the company’s stock, valued at approximately $16,239,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Parallel Advisors LLC boosted its holdings in shares of Sanofi by 42.5% during the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after acquiring an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC boosted its holdings in shares of Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after acquiring an additional 776 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Sanofi by 142.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after acquiring an additional 2,098 shares during the last quarter. Toronto Dominion Bank boosted its holdings in shares of Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after acquiring an additional 180 shares during the last quarter. Finally, Mraz Amerine & Associates Inc. purchased a new stake in shares of Sanofi during the 3rd quarter valued at about $204,000. Institutional investors and hedge funds own 9.30% of the company’s stock.

In other Sanofi news, major shareholder Sanofi acquired 105,820 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average price of $482.04 per share, with a total value of $51,009,472.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.00% of the company’s stock.

A number of analysts have recently issued reports on SNY shares. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price target (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Finally, Argus reaffirmed a “buy” rating and set a $55.00 price target on shares of Sanofi in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. Sanofi presently has a consensus rating of “Hold” and an average price target of $53.50.

COPYRIGHT VIOLATION NOTICE: “Renaissance Group LLC Acquires Shares of 326,142 Sanofi (SNY)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/renaissance-group-llc-acquires-shares-of-326142-sanofi-sny/1719888.html.

Sanofi (SNY) traded up $0.45 on Wednesday, hitting $45.24. 328,925 shares of the company were exchanged, compared to its average volume of 1,513,268. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. The stock has a market capitalization of $111,753.23, a P/E ratio of 13.98, a price-to-earnings-growth ratio of 2.44 and a beta of 0.88. Sanofi has a one year low of $38.45 and a one year high of $50.65.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.